PAR. SP, page-908

C'mon Mozz "reasonably received back then", seriously? We are living in the now and the hard truths are that none of the 32+ NDA signees (professionals from Pharma companies that do this for a living) recognised anything in the data room, that would have them want to stump up anything, or recommend to their boards that they should part with a small percentage of their R&D budgets.
In fact, here's what the top 20 R&D spends looked like back in 2022 and none of them decided PAR was worth any of their time or money.

Ranked by sales revenue

1			Nett Income 2022	R&D expense 2022	0m as % of R&D
2	#1-Pfizer	$31bn	$12.3bn	0.84%
3	J&J	$21.2bn	$14.6bn	0.68%
4	Roche	$13bn	$15bn	0.66%
5	Merck	$14.5bn	$11.8bn	0.85%
6	Abbvie	$11.7bn	$6.5bn	1.54%
7	Novartis	$6.9bn	$9bn	1.11%
8	Bristol Myers	$6.3bn	$9.4bn	1.06%
9	Sanofi	$8.8bn	$6.7bn	1.5%
10	AstraZenaca	$3.2bn	$9.6bn	1.04%
11	Glaxo	$18bn	$6bn	1.69%
12	#20- BionTech	$9bn	$2bn	5%
13